certolizumab pegol
Trade name: cimzia
mAbapproved
Approved
Apr 22, 2008
Certolizumab pegol, sold under the brand name Cimzia, is a biopharmaceutical medication for the treatment of Crohn's disease, rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. It is a fragment of a monoclonal antibody specific to tumor necrosis factor alpha (TNF-α) and is manufactured by UCB. — Wikipedia
Clinical trial activity
118 trials · 58 clinical orgs · 1 marketing orgs
Phase 1
12
Phase 2
79
Phase 3
61
Phase 4
21
Earliest trial started Oct 1, 2002 (NCT00544154)
Timeline
Indications
Approved for
Studied for
- Adenocarcinoma, Clear Cell · Phase 2
- Arthritis · Phase 3
- Arthritis, Juvenile · Phase 3
- Arthritis, Psoriatic · Phase 4
- Axial Spondyloarthritis · Phase 4
- Biliary Tract Neoplasms · Phase 1/Phase 2
- Chemoradiotherapy · Phase 2
- Claudins · Phase 1/Phase 2
- Colitis, Ulcerative · Phase 2
- Cystitis, Interstitial · Phase 3
- Drug Combinations · Phase 4
- Drug Therapy · Phase 1/Phase 2
- Embryo Implantation · Phase 3
- Esophageal Neoplasms · Phase 2
- Fibrosis · Phase 3
- General Surgery · Phase 2
- Healthy Volunteers · Phase 1
- Hypertension · Phase 4
- Immunotherapy · Phase 2
- Infertility, Male · Phase 1
- Lung Neoplasms · Phase 2
- Lupus Erythematosus, Systemic · Phase 2
- Melanoma · Phase 1
- Methotrexate · Phase 4
- Non-Radiographic Axial Spondyloarthritis · Phase 3
- Ovulation Induction · Phase 2
- Pregnancy Complications · Phase 2
- Pregnancy, High-Risk · Phase 2
- Psoriasis · Phase 3
- Rheumatic Diseases · Phase 2
- Sarcoma · Early Phase 1
- Spondylarthropathies · Phase 3
- Substance Withdrawal Syndrome · Phase 3
- Uveitis · Phase 4
- Vaginal Neoplasms · Phase 2
Mechanism of action
- TNF-alphaINHIBITOR
TNF inhibitor
Approval history
- approvedApr 22, 2008
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
- Multi-specific
- No
Oral
No
Parenteral
Yes
Topical
No
Black box warning
Sources
- WikipediaCertolizumab pegol ↗
- NCATSUMD07X179E ↗
- ChEMBLCHEMBL4297565 ↗
- ChEMBLCHEMBL1201831 ↗
Also known as
- cdp870
- cdp870
- cdp-870
- certolizumab
- certolizumab
- certolizumab pegol
- certolizumab pegol
- certolizumab pegol
- certolizumab pegol
- certolizumab pegol
- certolizumab pegol
- certolizumab pegol
- certolizumab pegol
- certolizumab pegol
- certolizumab pegol
- cimzia
- cimzia
- cimzia
- cimzia
- pha-738144
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07138898 | Phase 2 | Sep 30, 2025 | New York University |
| NCT06574412 | Phase 2 | Sep 1, 2024 | Jinlin University |
| NCT06421376 | Phase 2 | May 1, 2024 | Chinese Academy of Medical Sciences |
| NCT06292689 | Phase 2 | Mar 22, 2024 | Akeso Pharmaceuticals, Inc., Chinese Academy of Medical Sciences, Innovent Biologics (Suzhou) Co. Ltd. |
| NCT05930613 | Phase 3 | Nov 30, 2023 | Assistance Publique - Hôpitaux de Paris |
| NCT06028438 | Phase 2 | Aug 15, 2023 | — |
| NCT05994001 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2023 | Fudan University |
| NCT06114173 | Early Phase 1 (Phase 1) | Nov 1, 2022 | Central South University |
| NCT04991025 | Phase 2 | Nov 30, 2021 | Memorial Sloan-Kettering Cancer Center |
| NCT05115903 | Phase 4 | Nov 1, 2021 | University of Toronto |
| NCT04740814 | Phase 1 | Feb 11, 2021 | UCB |
| NCT04643483 | Phase 3 | Jan 31, 2021 | UCB |
| NCT04569890 | N/A | Dec 1, 2020 | Jiao Tong University |
| NCT04610476 | Phase 3 | Oct 31, 2020 | University of Erlangen-Nuremberg |
| NCT04163016 | Phase 1 | Dec 2, 2019 | UCB |
| NCT04123795 | Phase 3 | Nov 4, 2019 | UCB |
| NCT03445845 | Phase 4 | Sep 30, 2018 | University of Lyon |
| NCT03357471 | Phase 3 | Nov 3, 2017 | UCB |
| NCT03293784 | Phase 1 | Oct 16, 2017 | University of Toulouse |
| NCT03215277 | Phase 2 | Oct 4, 2017 | UCB |
Showing 20 of 118 trials
Page 1 / 6
Organizations
Research & Development (58)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hoosier Cancer Research Network | Academic/Hospital | 77 | 60 | 5 | 2002 |
| UCB | For profit | 8 | 8 | 4 | 2017 |
| Parexel | For profit | 7 | 0 | 3 | 2011 |
| Astellas | For profit | 4 | 4 | 1 | 2009 |
| Otsuka | For profit | 4 | 4 | 1 | 2008 |
| Dermira, Inc. | For profit | 3 | 0 | 1 | 2014 |
| Pharmaceutical Research Associates, Inc. (PRA) | For profit | 3 | 0 | 2 | 2012 |
| PPD | For profit | 3 | 0 | 2 | 2008 |
| University of Erlangen-Nuremberg | Academic/Hospital | 3 | 3 | 1 | 2009 |
| Assistance Publique - Hôpitaux de Paris | Academic/Hospital | 2 | 2 | 1 | 2007 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 2 | 2 | 1 | 2024 |
| Karolinska Institute | Academic/Hospital | 2 | 2 | 1 | 2012 |
| New York University | Academic/Hospital | 2 | 1 | 1 | 2017 |
| Shafran Gastroenterology Center | Academic/Hospital | 2 | 2 | 2 | 2010 |
| University of Toronto | Academic/Hospital | 2 | 1 | 2 | 2017 |
| Akeso Pharmaceuticals, Inc. | For profit | 1 | 0 | 1 | 2024 |
| Arthritis and Rheumatic Disease Specialties | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Arthritis Treatment Center, Frederick, Maryland | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Arthritis Treatment Center, Maryland | Academic/Hospital | 1 | 1 | 1 | 2011 |
| Atlanta Gastroenterology Associates | Academic/Hospital | 1 | 1 | 1 | 2009 |
58 organizations
Page 1 / 3